# Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients

> **NCT02572596** · NA · UNKNOWN · sponsor: **Wang Guorong** · enrollment: 200 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** rhTPO
- **DRUG:** CTX
- **DRUG:** -CSF

## Key facts

- **NCT ID:** NCT02572596
- **Lead sponsor:** Wang Guorong
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01-01
- **Primary completion:** 2017-12-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02572596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02572596, "Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02572596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*